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Abstract 
Introduction: Sofosbuvir is a new direct-acting pyrimidine nucleotide analogue 
antiviral drug with remarkable efficacy in clinical trials of Hepatitis C treatment. 
However, observational anecdotal data have recently suggested an increased risk of 
serious bradycardia among patients treated with sofosbuvir and amiodarone. Therefore, 
we aimed to better estimate and characterize the cardiac safety of sofosbuvir by 
performing a systematic review of randomized controlled trials (RCTs).  
Methods: Systematic review of RCTs (PROSPERO 2016:CRD42016033109) 
comparing sofosbuvir versus non-sofosbuvir regimens in chronic Hepatitis C patients. 
Medline, EMBASE and Cochrane Library were searched up to January 2016. Non-
published data was obtained from the sofosbuvir marketing authorization holder. 
Random-effects meta-analysis was performed to derive pooled estimates of Relative 
Risks (RR) and corresponding 95% Confidence Interval (CI).  
Results: Six trials enrolling 2346 patients (1625 treated with sofosbuvir) were included. 
The overall risk of bias across studies was moderate. The risk of reported cardiac events 
(RR 0.87; 95%CI 0.41 to 1.85), arrhythmias (RR 0.93, 95%CI 0.34 to 2.51), 
bradycardia (RR 0.47; 95%CI 0.04 to 5.20) and tachycardia were not significantly 
different between sofosbuvir and non-sofosbuvir regimens. The risks of reported 
syncope, presyncope or loss of consciousness, as well as palpitations were similar 
among sofosbuvir regimens and controls.  
Conclusion: The best comparative available evidence from RCTs do not suggest an 
increased risk of cardiac outcomes, in particular arrhythmias (including bradycardia), 
among sofosbuvir-treated patients, although the overall quality of the evidence 
supporting this conclusion is very low. 
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Introduction 
Sofosbuvir, a compound present in Sovaldi® (sofosbuvir), Harvoni® (sofosbuvir and 
ledispavir) and Epclusa® (sofosbuvir and velpatasvir), is a direct-acting pyrimidine 
nucleotide analogue antiviral drug approved to treat patients with chronic Hepatitis C 
Virus (HCV) infection. When administered in combination with a second direct-acting 
antiviral (DAA) agent, with and without pegylated interferon (PegIFN), sofosbuvir 
showed remarkable efficacy with about 90% of previously untreated patients with HCV 
infection achieving sustained virologic response.1 
In March 2015, the Food and Drug Administration (FDA) issued a label update for 
sofosbuvir, following a series of reports from Gilead Science, Inc describing 
symptomatic bradycardia events in nine patients treated with sofosbuvir with another 
DAA and amiodarone.2 In this update, bradycardia events were said to occur generally 
within hours to days, and a safety recommendation was made for patients who receive 
amiodarone to undergo cardiac monitoring for 48 hours after first administration.2 
These warnings were based on anecdotal case reports or small case series3,4. However, 
uncertainty exists regarding the pathophysiological mechanisms underlying this putative 
association between sofosbuvir and cardiac/bradycardia events. 
Therefore, we aimed to better estimate the risk of cardiac harms, with a special focus on 
arrhythmias, associated with sofosbuvir treatment by performing a systematic review of 
all randomized controlled trials (RCTs) comparing sofosbuvir with a control arm, 
independently of baseline conditions.  
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Methods 
This systematic review with meta-analysis was performed using Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) framework guidelines for 
reporting guidance,5 as well as its extension for improving harms reporting in 
systematic reviews (PRISMA harms).6. 
This systematic review was registered on PROSPERO (PROSPERO 
2016:CRD42016033109) and the protocol can be accessed at 
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016033109. 
 
Studies’ eligibility criteria 
We considered for inclusion all parallel design RCTs comparing any sofosbuvir-
containing regimen (including sofosbuvir alone or with other active drugs, irrespective 
of the dose, treatment duration or route of administration) with non-sofosbuvir control 
arm (either placebo or no treatment). Studies were excluded if both arms have been 
exposed to sofosbuvir, or if none of the cardiac safety outcomes of interest was 
reported. 
 
Cardiac safety was assessed by quantifying the risk of overall cardiac events (as defined 
by the System of Organ Classification – SOC – according to the MedDRA dictionary) 
reported in the RCTs, as well as the risk for arrhythmic events3,7, bradycardia3,7, 
tachycardia and extrasystoles (ventricular or supraventricular). Symptoms such as 
syncope, presyncope and loss of consciousness were also evaluated as potential 
surrogates of arrhythmic events. 
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Search method 
Potential eligible studies were searched through an electronic search in MEDLINE, 
EMBASE and Cochrane Library (CENTRAL), performed in January 2017. Search 
strategy (Supplementary Data 1) included free-text and MeSH (Medical Subjects 
Headings) terms without language restrictions. RCTs were identified through methods 
previously published 8,9. The reference lists of included studies as well as of other 
literature reviews were also comprehensively checked for other potential studies. 
Furthermore, we contacted the Clinical Research Department of Gillead Sciences, Inc to 
obtain further unpublished data. 
 
Data extraction, evaluation and synthesis 
Titles and abstract were screened independently by two authors.  RCTs who potentially 
fulfilled the inclusion criteria were further assessed in full-text. Study characteristics 
and outcomes were extracted independently by two authors. As anticipated, we found 
different reported terms for the same adverse event. Therefore, in addition to an 
individual appraisal of such data, we have aggregated the reported adverse events into 
clinically meaningful groups/outcomes/symptoms, such as arrhythmias, bradycardia, 
tachycardia or extrasystoles. For example, if palpitations were reported as an adverse 
event, and further information was provided for its cause, e.g. sinus tachycardia, we 
classified this adverse event into two different categories.   
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Risk of bias in individual studies 
We used the Cochrane tool for assessing risk of bias of included studies10. The six 
predefined specific domains of analysis were: random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, 
incomplete outcome data, and selective reporting. A domain to assess if the events were 
independently adjudicated was added.  Critical appraisal was performed independently 
by two authors. Any disagreement was solved by discussion and, if necessary, reached 
consensus with the participation of a third reviewer. The risk of bias was qualitatively 
evaluated as high, unclear or low risk. Risk of bias graphs were derived from this tool. 
 
Statistical analysis 
RevMan 5.3.3 software was used to calculate individual studies estimates and pooled 
analyses estimates. Results were reported using risk ratio (RR) and 95% confidence 
interval (95%CI). RR was chosen as effect measure for primary analysis due to greater 
similarity of relative estimates between studies with different designs, populations and 
lengths of follow-up.11 Raw data from studies was converted to RR, and random-effects 
pooled analysis was performed using the Mantel-Haenszel statistical methods, 
irrespectively of the statistical heterogeneity, as assessed with the I2 test.12 When one of 
the therapeutic arms presented zero events, a fixed value of 0.5 was added to avoid 
computational problems in the RR estimation 13,14. As the events of interest are deemed 
to be infrequent, and in order to indirectly assess the robustness of the results found in 
primary analysis with the above mentioned methods, we also derived pooled estimates 
using the following alternative methods: 1) Peto’s Odds Ratio (OR) 13; 2) Poisson 
random effects models for meta-analysis using the software R version 3.1.3, assuming 
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similarities in the RR and incident risk ratio in the case of rare events15; 3) Mantel-
Haenszel random effecs meta-analysis using the Risk Difference (RD) measure, in order 
to overcome the problems of zero events in both arms16. 
 
Assessment of confidence in cumulative evidence 
As recommended by the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group methodology17,18, two reviewers independently 
assessed all of the critical outcomes in the following domains: risk of bias, 
inconsistency, indirectness, imprecision and publication bias. In case of disagreement 
the authors reached consensus, consulting an independent third review if necessary. For 
this purpose, we used the GRADEprofiler (GRADEpro) software tool, which was then 
extract into the form of a summary of findings table for inclusion into the review 
manuscript. We applied the standard definitions of the quality of evidence19 and explicit 
criteria to ensure the consistency and reproducibility of GRADE judgements for each 
domain and for all key comparisons of the critical outcomes (Supplementary Data 2). 
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Results 
Included trials 
Overall, six trials with 2346 patients fulfilled the inclusion criteria (Figure 1)20-25. A 
total 1625 patients were treated with sofosbuvir, either alone or in combination with 
other agents, such as ribarivin ± peginterferon (57%), velpatasvir (38%) or ledispavir 
(5%). Among controls, 349 patients were treated with placebo (4 trials), 243 patients 
were treated with the combination of interferon and ribavirine (1 trial), and 129 patients 
received the combination of elbasvir and grazoprevir (1 trial).  
The mean age of patients in the trials ranged from 48 to 64 years, and the proportion of 
cirrhotic patients ranged from 16 to 100% among the trials. 
Table 1 overviews the characteristics of the included trials. 
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Figure 1: Flowchart of studies selection. 
 
Risk of bias 
The overall risk of bias across studies was moderate. The included trials had different 
methodologic approaches which limits, at least partially, the robustness of data. All 
trials used adequate methods to randomize to therapeutic arms, but three trials were 
unblinded for the randomized arms: both FISSION and C-EDGE head-2-head trials had 
a priori an open-label design21,25, while in the VALENCE study22 randomization codes 
were revealed to terminate with the placebo arm due to the efficacy data reported in the 
FISSION trial21. In these trials the report of any adverse events could be done 
unblinded. Regarding the outcomes of interest of this systematic review, none was 
previously determined, and thus such events were not actively searched. None of 
adverse events reported was independently adjudicated. Figure 2 details the risk of bias 
assessment and Supplementary Figure 1 overviews the proportion of included trials that 
were at low or high risk of bias for each domain ascertained. 
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Figure 2: Risk of bias assessment results of each trial. Green symbols are associated to low risk 
of bias features, and red symbols mean high risk of bias. 
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Table 1: Main characteristics of included trials. 
Study	  
Year	  of	  
publication	  
Type	  of	  RCT	   Patients	   N	   Intervention	   Control	   Age	  
(years)	  /	  
Male	  (%)	  
Cirrhosis	  
(%)	  
Follow-­‐up	  
FISSION	  
2013	  
Multicentric	  
Open-­‐label	  
Treatment-­‐naïve	  patients	  with	  
HCV	  genotype	  2	  or	  3	  infection	  
499	   Sofosbuvir	  +	  
Ribavirin	  	  
(n=256)	  
Peginterferon	  +	  
Ribavirin	  
(n=243)	  
48/66%	   20%	   12	  weeks	  after	  
the	  end	  of	  the	  
treatment	  
POSITRON	  
2013	  
Multicentric	  
Blinded	  
HCV	  genotype	  2	  or	  3	  infection	  
in	  whom	  treatment	  with	  
pegylated	  interferon	  and	  
ribavirin	  was	  not	  an	  option	  
278	   Sofosbuvir	  +	  
Ribavirin	  
(n=207)	  
Placebo	  
(n=71)	  
52/54%	   16%	   12	  weeks	  
VALENCE	  
2014	  
Multicentric	  
Blinded	  
Unblinding	  due	  to	  
results	  of	  FISSION.	  
Placebo	  group	  was	  
terminated	  
HCV	  genotype	  2	  or	  3	  infection	   419	   Sofosbuvir	  +	  
Ribavirin	  
(n=334)	  
Placebo	  
(n=85)	  
Early	  stop	  
50/60%	   21%	   24	  weeks	  
7	  weeks	  for	  
placebo	  group	  	  
ASTRAL-­‐1	  
2015	  
Multicentric	  
Blinded	  
Previously	  treated	  patients	  
with	  chronic	  HCV	  genotype	  1,	  
2,	  4,	  5,	  or	  6	  infection	  
740	   Sofosbuvir	  +	  
velpatasvir	  
(n=624)	  
Placebo	  
(n=116)	  
64/60%	  	   19%	   12	  weeks	  
SIRIUS	  
2015	  
Multicentric	  French	  
trial	  
Blinded	  
HCV	  genotype	  1	  and	  
compensated	  cirrhosis	  who	  
had	  not	  achieved	  SVR	  with	  
previous	  pegylated	  interferon	  
and	  protease	  inhibitor	  
155	   Sofosbuvir	  +	  
Ledispavir	  
(n=77)	  
Placebo	  in	  the	  
first	  12	  weeks	  
(n=78)	  
57/74%	   100%	   First	  12	  weeks	  
of	  the	  trials	  
C-­‐EDGE	  
Head-­‐2-­‐
Head	  
2016	  
Multicentric	  
Open-­‐label	  
HCV	  genotype	  1	  or	  4	  infection	  
and	  baseline	  viral	  load	  >10000	  
IU/ml	  
255	   Sofosbuvir	  +	  
Peginterferon	  +	  
Ribavirin	  
(n=126)	  
Elbasvir	  +	  
Grazoprevir	  
50/46%	   17%	   12	  weeks	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Primary analysis 
The pooled analysis included both published and unpublished data (provided by Gilead 
Sciences, Inc.) from the 6 RCTs and showed that sofosbuvir was not associated with an 
increased risk of reported cardiac events (SOC cardiac), with a RR 0.87 (95%CI 0.41 to 
1.84, I2=7%, n=2346) (Figure 3). The risk of overall arrhythmic events was also not 
different between sofosbuvir regimens and non-sofosbuvir treatments (RR 0.93, 95%CI 
0.34 to 2.51, I2=0%, n=2091). As for bradycardia, only the FISSION trial reported such 
events: one sinus bradycardia in each arm, and one complete atrioventricular block in 
the interferon and ribavirine arm (non-sofosbuvir arm)21. The RR for bradycardia was 
0.47 (95%CI 0.04 to 5.20, n=499). 
The pooled relative risk of tachycardia (RR 1.13, 95%CI 0.28 to 4.51, I2=0%, n=1351) 
and extrasystoles (RR 1.22, 95%CI 0.25 to 5.89, I2=0%, n=2091) were not significantly 
different among sofosbuvir and non-sofosbuvir regimens. 
Symptoms reported as adverse events potentially related to arrhythmias such as 
syncope, presyncope or loss of consciousness were reported in 3 trials (Figure 4). The 
pooled analyses of both individual outcomes (Supplementary Figure 2) and the 
composite of such reported adverse events (RR 0.70, 95%CI 0.26 to 1.88, I2=0%, 
n=1517) did not show an increased risk with sofosbuvir treatment. Similarly, the 
relative frequency of palpitations as a reported adverse event was not increased with 
sofosbuvir (RR 0.62, 95%CI 0.24 to 1.60, I2=0%, n=1936). 
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Figure 3: Forest plot evaluating the relative risk of reported cardiac events, arrhythmias, 
bradycardia, tachycardia, and extrasystoles. 
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Figure 4: Forest plot evaluating the relative risk of the reported palpitations and cumulative 
outcome of syncope, presyncope or loss of consciousness. 
 
Additional analyses 
The results from pooled analyses using alternative methods and/or estimate measures 
were similar to the findings of primary analysis, without significant differences between 
groups for all outcomes (Table 2). 
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Table 2: Risk of cardiac harms with sofosbuvir using alternative methods and/or estimate measures. 
	   Peto’s	  OR	  [95%CI]	   Poisson	  model	  –	  RR	  
[95%CI]	  
Risk	  difference	  (%)	  
[95%CI]	  
All cardiac events (SOC 
cardiac) 
0.90 [0.47, 1.72] 0.91 [0.38, 2.18] 0.3% [-1.1, 1.8] 
All arrhythmic events 1.21 [0.46, 3.21] 1.11 [0.41, 3.00] 0.3% [-0.6, 1.2] 
Bradycardia 0.49 [0.05, 4.69] N/A -0.1% [-0.8, 0.6] 
Tachycardia 1.24 [0.33, 4.70] 1.38 [0.32, 6.07] 0.2% [-0.9, 1.4] 
Extrasystoles 4.35 [0.57, 33.50] N/A 0.3% [-0.4, 1.0] 
Syncope, presyncope or 
loss of consciousness 
0.82 [0.30, 2.21] 0.73 [0.27, 1.97] 0.2% [-0.7, 1.0] 
Palpitations 0.65 [0.26, 1.64] 0.64 [0.28, 1.46] -0.2% [-1.4, 0.8] 
 
 
Assessment of confidence in cumulative evidence 
Supplementary Table 1 details the GRADE approach for the quality of the available 
evidence which was considered to be very low. 
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Discussion 
This systematic review overviewed cardiac events, which are of concerning in patients 
treated with sofosbuvir according to the last reports3,7. 
Among the cardiac adverse events, arrhythmias, predominantly severe 
bradydysrhythmia, were deemed to be associated with sofosbuvir in particular 
circumstances. 
Our systematic review and meta-analysis of RCTs evaluating sofosbuvir and non-
sofosbuvir regimens (including placebo), did not raise any safety concerns regarding 
cardiac, arrhythmic or bradycardia risk. Complementarily, the analysis of reported 
adverse events related to symptoms linked to (but not pathognomonic of) dysrhythmias, 
such as syncope, presyncope, loss of consciousness, and palpitations was unremarkable 
for any safety warning issue, despite the acknowledged limitations (see Limitations 
section ahead). 
Even though, the risk of arrhythmic events in patients with chronic liver disease and the 
potential causality with sofosbuvir (with or without amiodarone) should be addressed 
recognizing that some bias and drawbacks may exist. First, arrhythmias are not unusual 
in patients with chronic liver disease including cirrhosis26-29, and it is also known that 
the use of non-selective beta-blockers to decrease the portal pressure, further impairs the 
cardiac chronotropism and dromotropism30. Second, there are events occurring in 
patients without amiodarone7. Third, the causality relationship between sofosbuvir (and 
amiodarone) and the onset of bradycardia in the case reports and case-series is 
methodologically doubtful3,7. Thus, a reasonable uncertainty exists regarding sofosbuvir 
and the risk of cardiac/arrhythmic/bradycardic events. 
Still, in 2015, the FDA issued a label update for both sofosbuvir and the combination of 
sofosbuvir and ledipasvir31. Gilead Sciences, Inc also issued a warning letter to 
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physicians informing that both formulations of sofosbuvir may cause potentially fatal 
heart arrhythmias. 
In our opinion, the present findings are of utmost clinical relevance: DAA are becoming 
the standard of care for hepatitis C treatment and the number of patients exposed to 
sofosbuvir is expected to be increasing in a proportion that exceeds the number of 
patients included the clinical trials. It is worth noting that the possibility of a small 
absolute risk increase is not excluded by our analysis and therefore larger observational 
studies or phase IV trials with longer follow-up will definitely contribute to the 
evaluation of cardiac risks associated with DAA, particularly sofosbuvir. 
 
Limitations 
Results and conclusion here presented are weakened by limitations inherent to meta-
analysis and individual studies. The higher risk of bias was found for potential selective 
reporting. A key limitation is that there is not a single RCT primarily designed to assess 
the cardiac/arrhythmic safety of sofosbuvir and these outcomes were not actively 
searched. Furthermore, reporting of cardiac events was at the discretion of the 
investigator. Another limitation of our findings is related to the low rates of cardiac 
events. In the sofosbuvir arms, the risk of overall cardiac events was about 2.0%. 
Although the data from cardiac safety warnings points to potential short-term cardiac 
adverse events, it should be acknowledged that the follow-up period was considerably 
short and does not rule out the risk of long-term cardiac events. Even though, and 
considering these limitations, we claim that our results represent the best possible 
available evidence about this topic, which was raised by anecdotic case reports of 
potential idiosyncratic reactions that occurred in the first 48 hours in patients taking 
amiodarone and sofosbuvir. 
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Conclusions 
The best available evidence from RCTs does not confirm sofosbuvir as a harmful drug 
regarding short-term cardiac events, including (brady)arrhythmias.  
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Supplementary Data 1 
 
Search strategy 
 
Database: MEDLINE and Cochrane Library (CENTRAL) via Ovid 
 
1. Exp sofosbuvir/ 
2. Sofosbuvir.af 
3. Sovaldi.af 
4. Virunon.af 
5. Harvoni.af 
6. 1 or 2 or 3 or 4 or 5 
7. randomized controlled trial.pt. 
8. controlled clinical trial.pt. 
9. randomized.ab. 
10. drug therapy.fs. 
11. randomly.ab. 
12. trial.ab. 
13. groups.ab. 
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. exp animals/ not humans.sh. 
16. 14 not 15 
17. 6 and 16 
 
 
Database: Embase Classic+Embase 
 
1. exp sofosbuvir/ 
2. (sofosbuvir or sovaldi or virunon or harvoni).ti,ab. 
3. 1 or 2 
4. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. 
5. RETRACTED ARTICLE/ 
6. 4 or 5 
7. (animal$ not human$).sh,hw. 
8. (book or conference paper or editorial or letter or review).pt. not exp randomized 
controlled trial/ 
9. (random sampl$ or random digit$ or random effect$ or random survey or 
random regression).ti,ab. not exp randomized controlled trial/ 
10. 7 or 8 or 9 
11. 6 not 10 
12. 3 and 11 
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Supplementary Data 2 
 
Definitions of the quality of evidence and criteria to each domain for all key 
comparisons of the critical outcomes. 
Definitions of the quality of evidence: -­‐ High quality: We are very confident that the true effect lies close to that of the 
estimate of the effect -­‐ Moderate quality: We are moderately confident in the effect estimate; the true 
effect is likely to be close to the estimate of the effect, but there is a possibility 
that it is substantially different -­‐ Low quality: Our confidence in the effect estimate is limited; the true effect may 
be substantially different from the estimate of the effect -­‐ Very low quality: We have very little confidence in the effect estimate; the true 
effect is likely to be substantially different from the estimate of effect 
 
Criteria to each domain for all key comparisons of the critical outcomes: -­‐ Study limitations: downgraded once if more than 30% of participants were from 
studies classified as being at a high risk of bias across any domain. -­‐ Inconsistency: downgraded once if heterogeneity is statistically significant or if 
the I2 value is more than 40%. When a meta-analysis was not performed we 
downgraded once if trials did not show effects in the same direction. 
23	  
	  
-­‐ Indirectness: downgraded once if more than 50% of the participants were outside 
the target group. -­‐ Imprecision: downgraded once if fewer than 300 events for dichotomous data. -­‐ Publication bias: downgraded once where there is direct evidence of publication 
bias or if estimates of effect were based on small scale, industry-sponsored 
studies raising a considerable suspicion of publication bias. 
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Supplementary Figure 1: Risk of bias graph: review authors' judgements about each risk 
of bias item presented as percentages across all included studies. 
 
 
 
Supplementary Figure 2: Forest plot evaluating the relative risk of the reported syncope, 
presyncope or loss of consciousness associated to sofosbuvir regimens. 
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Supplementary Table 1 – Summary of findings table according to the GRADE 
approach. 
Anticipated absolute effects (95% CI)  Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Without Sofosbuvir With Sofosbuvir Difference 
Quality  
All cardiac events (SOC cardiac) 
№ of participants: 2346 
(6 RCTs)  
RR 0.87 
(0.41 to 1.82)  
2.2%  1.9% 
(0.9 to 4.0)  
0.3% fewer 
(1.3 fewer to 
1.8 more)  
 ◯◯◯ 
VERY LOW 
a,b 
All arrhythmic events 
№ of participants: 2091 
(5 RCTs)  
RR 0.93 
(0.34 to 2.51)  
1.0%  0.9% 
(0.3 to 2.5)  
0.1% fewer 
(0.7 fewer to 
1.5 more)  
 ◯◯◯ 
VERY LOW 
a,b 
Bradycardia 
№ of participants: 499 
(1 RCT)  
RR 0.47 
(0.04 to 5.20)  
0.8%  0.4% 
(0.0 to 4.3)  
0.4% fewer 
(0.8 fewer to 
3.5 more)  
 ◯◯◯ 
VERY LOW 
a,b 
Tachycardia 
№ of participants: 1351 
(4 RCTs)  
RR 1.13 
(0.28 to 4.51)  
0.6%  0.7% 
(0.2 to 2.8)  
0.1% more 
(0.5 fewer to 
2.2 more)  
 ◯◯◯ 
VERY LOW 
a,b 
Extrasystoles 
№ of participants: 1936 
(4 RCTs)  
RR 1.22 
(0.25 to 5.89)  
0.0%  0.0% 
(0.0 to 0.0)  
0.0% fewer 
(0 fewer to 0 
fewer)  
 ◯◯◯ 
VERY LOW 
a,b 
Syncope, presyncope or loss of consciousness 
№ of participants: 1517 
(3 RCTs)  
RR 0.70 
(0.26 to 1.88)  
1.9%  1.3% 
(0.5 to 3.5)  
0.6% fewer 
(1.4 fewer to 
1.6 more)  
 ◯◯◯ 
VERY LOW 
a,b 
Palpitations 
№ of participants: 1936 
(4 RCTs)  
RR 0.62 
(0.24 to 1.60)  
1.7%  1.1% 
(0.4 to 2.8)  
0.7% fewer 
(1.3 fewer to 
1 more)  
 ◯◯◯ 
VERY LOW 
a,b 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect; Moderate quality: We are moderately confident in the 
effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low quality: Our 
confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; Very low quality: We have very little 
confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
a. Serious study limitations: the limitations in the studies assessing this outcome are serious and affect our confidence in the accuracy of the effect 
estimate  
b. Very serious imprecision: the total number of participants included was less than 10% of the number generated by a conventional sample size 
calculation single adequately powered superiority trial (alpha=0.05, beta=0.20)  
